Overview

• The FDA has issued a warning about Librela, a monoclonal antibody injection for dogs with osteoarthritis, citing over 3,600 reported cases of adverse effects between 2023 and March 2024.
• Reported side effects include seizures, ataxia, paresis, urinary incontinence, excessive thirst and urination, and in severe cases, death or euthanasia.
• Librela, manufactured by Zoetis, was approved by the FDA in May 2023 and has been administered to millions of dogs worldwide, with the company maintaining its safety and efficacy claims.
• Veterinarians are urged to report any adverse effects observed in dogs treated with Librela to Zoetis or directly to the FDA for further investigation.
• The FDA's alert follows growing concerns from pet owners, veterinarians, and online communities about the drug's safety, as well as calls for additional scrutiny and potential label updates.